Skip to main content
MRK
NYSE Life Sciences

默克公司收购Terns Pharma，通过新型CML候选药物TERN-701增强血液学管道

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$116.68
Mkt Cap
$287.712B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

默克公司正式宣布收购Terns Pharmaceuticals, Inc.，这是为了扩大其血液学管道的战略举动。该收购特别针对TERN-701，一种用于慢性髓性白血病（CML）的新型候选药物。该声明证实了路透社早些时候的报道，即默克公司正在进行高级谈判，以大约60亿美元的价格收购Terns。对于像默克这样的大型制药公司来说，该收购具有重要意义，提供了新的增长途径，并使其未来的产品组合多样化，这在其关键产品Keytruda因专利到期和IRA价格设定而预计出现收入下滑的背景下至关重要，如其最近的10-K所强调。交易者现在将关注该交易的财务细节和TERN-701的开发时间表。

在该公告发布时，MRK的交易价格为$116.68，交易所为NYSE，所属行业为Life Sciences，市值约为$2877.1亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article